Clinical trials · Massachusetts
Prostate cancer clinical trials in Massachusetts
We’re tracking 86 recruiting prostate cancer studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Boston, MassachusettsAges 18 years+ - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Boston, MassachusettsAges 18 years+ - NCT05129605Recruiting
Prostate cancer genetic risk screening study for men
This study looks at your personal and family risk for prostate cancer and helps decide who should have extra screening like MRI. It may help you find cancer earlier if you are at higher genetic risk.
Boston, MassachusettsAges 35–74 - NCT07719361RecruitingPhase 1
New drug for advanced, treatment-resistant prostate cancer
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
Boston, MassachusettsAges 18 years+ - NCT06579417Recruiting
Testing a faster MRI for prostate cancer detection
This trial is testing a new, faster type of MRI scan (called biparametric MRI) to see if it can detect prostate cancer as well as the standard scan. It may help you avoid a longer scan and possibly reduce the need for contrast dye.
Boston, MassachusettsAges 18 years+ - NCT07581184RecruitingPhase 1
Targeted Radioactive Therapy for Advanced Prostate Cancer
This Phase 1 trial tests a new radioactive treatment called [225Ac]Ac-AKY-2519 in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug carries radioactivity directly to cancer cells to try to shrink tumors and slow disease progression.
Boston, MassachusettsAges 18 years+ - NCT07393867RecruitingPhase 2
PSMA-guided radiation boost for prostate cancer
This trial tests a special type of radiation therapy (SBRT) that delivers a higher dose directly to the main tumor in your prostate, guided by a PSMA PET scan. It aims to improve cancer control while limiting side effects.
Milford, MassachusettsAges 18 years+ - NCT07192614RecruitingPhase 1/Phase 2
Study of AZD6621 for men with advanced prostate cancer
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
Boston, MassachusettsAges 18 years+ - NCT07059884Recruiting
Exercise program to help people with cancer stay active
This trial tests a distance-based exercise program designed to help people on chemotherapy maintain their physical function and prevent disability. It is for patients with certain cancers who are working full-time and can participate in moderate physical activity.
Boston, MassachusettsAges 18 years+ - NCT06957691RecruitingPhase 2
Fezolinetant for hot flashes in men on hormone therapy
This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.
Boston, MassachusettsAges 40 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after prior treatment
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
Boston, MassachusettsAges 18 years+ - NCT06801236RecruitingPhase 1
A new drug for advanced prostate cancer that has stopped responding to treatment
This early-phase trial tests a new study drug called ACE-232 for men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It aims to see if the drug is safe and may help slow the cancer.
Boston, MassachusettsAges 18 years+ - NCT06517901Recruiting
Comparing two MRI-guided biopsy methods for prostate cancer
This trial compares two ways to use MRI images during a prostate biopsy to see which finds cancer better. It looks at 'fusion' biopsy (where a computer combines MRI with live ultrasound) versus 'cognitive' biopsy (where the doctor mentally matches the MRI to the ultrasound).
Burlington, MassachusettsAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Boston, MassachusettsAges 18 years+ - NCT06398639Recruiting
Using genetic risk and MRI to find dangerous prostate cancer
This study uses a genetic risk score and a special MRI scan to find prostate cancers that are more likely to be dangerous. It aims to see if combining these tests can better identify which men need a biopsy.
Boston, MassachusettsAges 40–69 - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Worcester, MassachusettsAges Any age - NCT06062745RecruitingPhase 1
PET scan study for prostate cancer with low PSMA or neuroendocrine features
This study tests a special PET scan (fluciclovine) to see if it can better detect prostate cancer that has low PSMA levels or has changed to a neuroendocrine type. It may help find tumors that standard PSMA scans miss.
Boston, MassachusettsAges 18 years+ - NCT06040125Recruiting
Exercise for frailty and muscle loss in men with prostate cancer
This trial tests a supervised exercise program to see if it can reduce frailty and muscle loss in men with metastatic prostate cancer who are on hormone therapy. It may help you become stronger and feel better during treatment.
Boston, MassachusettsAges 18 years+ - NCT05946213RecruitingPhase 3
Shorter radiation treatment for high-risk prostate cancer
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
Milford, MassachusettsAges 18 years+ - NCT05804318Recruiting
Adaptive daily radiation for low- and intermediate-risk prostate cancer
This trial tests a radiation plan that is adjusted every day using your own scans to better target prostate cancer. It may help reduce side effects while still treating the cancer effectively in men with lower- or intermediate-risk disease.
Boston, MassachusettsAges 18 years+ - NCT05327465Recruiting
Exercise program for Black men on prostate hormone therapy
This trial tests whether a structured exercise program can improve heart and blood-vessel health in Black men receiving androgen deprivation therapy for prostate cancer. It may help your cardiovascular (heart) health and monitors safety during the program.
Boston, MassachusettsAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Jamaica Plain, MassachusettsAges 40–75 - NCT05225428Recruiting
Video education program based on personal genetic result disclosure
This study tests a video-based education approach that shares information differently depending on someone’s genetic test results. It may help people better understand cancer-related genetic information and what it could mean for them.
Boston, MassachusettsAges 18 years+ - NCT04946370RecruitingPhase 1/Phase 2
Pembrolizumab plus prostate cancer drug, with or without radiation
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
Boston, MassachusettsAges 18 years+
Prostate cancer trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting prostate cancer studies listed above.
- Dana-Farber Cancer Institute · 12 studies
- Brigham and Women's Hospital · 7 studies
- Massachusetts General Hospital · 6 studies
- Beth Israel Deaconess Medical Center · 2 studies
- Boston Veteran's Affairs Medical Center
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center
- Dana-Farber/Brigham and Women's Cancer Center at South Shore
What taking part in a prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Prostate cancer trials in other states
Common questions
- Are there prostate cancer clinical trials in Massachusetts?
- Yes. We're currently tracking 86 recruiting prostate cancer studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a prostate cancer study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New prostate cancer studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.